文献速递新发突发、热带与寄生虫病

抗疟药群体给药增加还是降低耐药风险?

Does antimalarial mass drug administration increase or decrease the risk of resistance?
PubMed 文献 · Lancet Infect Dis · 2016-11-11

本文讨论抗疟药群体给药(MDA)在何种情况下增加或降低耐药风险。作者指出,耐药风险取决于暴露寄生虫总数及其个体存活与传播概率,而非携带者人数;在疟疾流行区,无症状感染者寄生虫负荷远低于有症状者且宿主防御更有效,因此有效群体治疗减少有症状病例及传播,可降低耐药出现与扩散的威胁。

要点

  • 耐药风险取决于暴露寄生虫总数及存活传播概率,而非人数。
  • 无症状感染者寄生虫负荷远低于有症状者,宿主防御更有效。
  • 有效MDA减少有症状病例和传播,可降低耐药威胁。

核心结论

  • 抗疟药MDA对耐药风险的影响取决于暴露寄生虫总数及其个体存活与传播概率,而非携带者人数。
  • 在疟疾流行区,有效群体治疗减少有症状病例及传播,可降低耐药出现与扩散的威胁。

研究设计与样本

  • 本文为Personal View,讨论抗疟药MDA增加或降低耐药风险的情形。

主要发现

  • 在疟疾流行区,相当比例社区成员血中携带疟原虫但无症状。
  • 无症状感染者寄生虫负荷比有症状者低数个数量级,宿主防御机制更有效。
  • 有症状感染且寄生虫数量高是最可能的耐药出现来源。

关键数值与推荐

  • 耐药风险由暴露寄生虫总数及其个体存活与传播概率决定,而非携带者人数。

临床怎么用

  • 实施有效群体治疗以减少有症状疟疾病例及其传播,从而降低耐药出现与扩散威胁。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

All antimalarial drugs developed so far have eventually succumbed to resistance. There is a general belief that the more people that are exposed to an antimalarial drug, the more likely it is that resistance will emerge. Mass drug administration (MDA) is therefore considered a potent cause of antimalarial drug resistance. In this Personal View, I discuss the circumstances under which antimalarial MDA increases or decreases the risk of resistance. It is the total number of parasites exposed and their individual probabilities of survival and spread that determine the risk, not the number of people that contain them. In malaria-endemic areas, a substantial proportion of the community carries malaria parasites in their blood without being ill. Although many more people have asymptomatic than symptomatic malaria at any time, their parasite burdens are several orders of magnitude lower, and their host defence mechanisms are substantially more effective. Symptomatic infections with high parasite numbers are the most likely source of resistance emergence, so effective mass treatment that reduces the number of symptomatic cases of malaria and its transmission can reduce the threat of antimalarial resistance emerging and spreading in treated populations.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. White NJ. Does antimalarial mass drug administration increase or decrease the risk of resistance? Lancet Infect Dis. 2016. PMID: 27839929. doi:10.1016/S1473-3099(16)30269-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。